{"TopicDetails": {"type": 0, "ccm2Id": 31073855, "cftId": 0, "identifier": "IMI2-2015-07-01", "title": "VALIDATION OF TRANSLATIONAL IMAGING METHODS IN DRUG SAFETY ASSESSMENT (TRISTAN)", "publicationDateLong": 1450396800000, "callIdentifier": "H2020-JTI-IMI2-2015-07-two-stage", "callTitle": "H2020-JTI-IMI2-2015-07-two-stage", "callccm2Id": 31073864, "allowPartnerSearch": true, "workProgrammepart": {"id": 3051, "ccm_id": 31078048, "wp_part": "H2020-JTI-IMI-2016", "wp_year": "H2020-JTI-IMI-2016", "wp_title": "IMI2 Work Plan 2016", "wp_website": "http://www.imi.europa.eu/", "wp_document": "http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp16-imi_en.pdf"}, "frameworkProgramme": {"id": 31045243, "abbreviation": "H2020", "description": "Horizon 2020 Framework Programme"}, "programmeDivision": [{"id": 31047894, "abbreviation": "EU.3.1.", "description": "Health, demographic change and wellbeing"}, {"id": 31047893, "abbreviation": "EU.3.", "description": "Societal Challenges"}, {"id": 31045244, "abbreviation": "EC", "description": "EC Treaty"}], "topicMGAs": [], "tags": ["Toxicology", "Imaging", "Safety Pharmacology"], "keywords": ["Safety Pharmacology", "Biomarkers", "Pharmaceutical development", "Translational medicine", "Chronic toxicity", "Pharmacology, pharmacogenomics, drug discovery and", "Radiology, nuclear medicine and medical imaging", "Acute toxicity"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "IMI2-RIA Research and Innovation action", "typeOfMGA": []}], "plannedOpeningDate": "18 December 2015", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["17 March 2016", "06 September 2016"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3226318": [{"action": "IMI2-2015-07-03 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 December 2015", "deadlineModel": "two-stage", "deadlineDates": ["17 March 2016", "06 September 2016"], "budgetYearMap": {"2015": 93604000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2015-07-07 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 December 2015", "deadlineModel": "two-stage", "deadlineDates": ["17 March 2016", "06 September 2016"], "budgetYearMap": {"2015": 93604000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2015-07-02 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 December 2015", "deadlineModel": "two-stage", "deadlineDates": ["17 March 2016", "06 September 2016"], "budgetYearMap": {"2015": 93604000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2015-07-01 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 December 2015", "deadlineModel": "two-stage", "deadlineDates": ["17 March 2016", "06 September 2016"], "budgetYearMap": {"2015": 93604000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2015-07-04 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 December 2015", "deadlineModel": "two-stage", "deadlineDates": ["17 March 2016", "06 September 2016"], "budgetYearMap": {"2015": 93604000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2015-07-05 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 December 2015", "deadlineModel": "two-stage", "deadlineDates": ["17 March 2016", "06 September 2016"], "budgetYearMap": {"2015": 93604000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2015-07-06 - IMI2-CSA Coordination & support action", "plannedOpeningDate": "18 December 2015", "deadlineModel": "two-stage", "deadlineDates": ["17 March 2016", "06 September 2016"], "budgetYearMap": {"2015": 93604000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2015"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p>The development of imaging biomarkers both for the pre-clinic and the clinic has the potential to advance safety evaluation. However, in order for imaging biomarkers to become more mainstream, impacting the drug discovery process more widely, there needs to be technical advances, as well as a better standardization across the imaging community to ensure protocols, biomarkers, analysis and data interpretation are well recognized and equivalent. If properly validated, imaging methods will support establishment of the ADME concept and estimation of toxic effects of drug candidates and could additionally strongly support the efforts to identify the minimal (i.e. safest) dose providing useful therapeutic efficacy.</p><p>Please refer to the full topic text on the IMI2 Call 7 section of the IMI website.</p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The overall aim of the proposal is to leverage the potential of available imaging techniques in order to improve drug safety analysis and translatability of findings from animals to humans by validating imaging procedures as biomarker. The output from the resulting project should provide clear evidence that state-of-the-art imaging techniques, when validated properly, can support pre-clinical and clinical drug development and improve safety for individual patients. The following three areas are in scope: the assessment of liver toxicity; lung toxicity and the bio-distribution of biologicals.</p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p>The information and knowledge acquired will be of outmost value for further improving safety evaluation of novel drug candidates, small molecules as well as biologics. Imaging biomarkers have a strong potential to improve translatability of pre-clinical results to healthy volunteers and patients and thus help to avoid late stage attrition of development programs. In addition, functional diagnostic imaging methods used as biomarkers would offer the possibility to confirm drug toxicity mechanisms in humans, including the potential to determine drug-drug interactions.</p><p>The possibility to follow a drugs bio-distribution and its effect on tissues or molecules longitudinally by means of imaging intrinsically includes the potential to reduce animal numbers in pre-clinical studies. Hence the work in this program strongly supports the 3R principle (refinement, reduction, replacement) in substantially reducing the number of animals needed in pre-clinical research.</p><p>Please refer to the full topic text on the IMI2 Call 7 section of the IMI website.</p>\n", "conditions": "<p>Please read carefully all provisions below before the preparation of your application.</p>\r\n<p>You can access the <strong>description of the different topics</strong> in the <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche15-7-imi2-ju_en.pdf\">Call topics text</a>.</p>\r\n<p>The <strong>budget breakdown</strong> for this Call is given at the end of the Call topics text, in the <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche15-7-imi2-ju_en.pdf\">Call Conditions</a> section (page 78), as well as the following information :&nbsp;<br />\r\n&nbsp;</p>\r\n<ol>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">List of countries and applicable rules for funding</span></strong><br />\r\n    &nbsp;</li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Eligibility and admissibility conditions</span></strong><br />\r\n    &nbsp;</li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Evaluation criteria and procedure, scoring and threshold : </span></strong><span style=\"color: rgb(0,51,102)\">described in the <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.2_en.pdf\">IMI</a></span><a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.2_en.pdf\">&nbsp;Manual for Submission, Evaluation and Grant award</a><br />\r\n    &nbsp;</li>\r\n    <li><span style=\"color: rgb(0,51,102)\"><strong>Indicative timetable for evaluation and grant agreement</strong></span><br />\r\n    &nbsp;</li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:</span></strong><br />\r\n    <br />\r\n    <u>IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):</u><br />\r\n    <br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-rel-prov-imi-ju_en.pdf\">Summary of the most relevant provisions for participating in IMI2 actions</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-03-01/1635128-imi2_proposal-template_ria-ia_en.pdf\">Standard proposal template</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/ef/h2020-call-ef-imi2-ria-ia-2016_en.pdf\">Standard evaluation form</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-mga-imi_en.pdf\">IMI2 Model Grant Agreement</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/h2020-phc-2015-two-stage/1620124-essential_information_for_clinical_studies_2015callsv2_18082014_en.pdf\">Template for Essential Clinical Trials Information</a><br />\r\n    <br />\r\n    <u>MI2 Coordination and Support Action (IMI2-CSA):</u><br />\r\n    <br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-rel-prov-imi-ju_en.pdf\">Summary of the most relevant provisions for participating in IMI2 actions</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-04-01/1635139-imi2_proposal-template_csa_en.pdf\">     Standard proposal template</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-04-01/1635140-imi2_evaluation-form_csa_en.pdf\">     Standard evaluation form</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-mga-imi_en.pdf\">IMI2 Model Grant Agreement<br />\r\n    </a><a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/h2020-phc-2015-two-stage/1620124-essential_information_for_clinical_studies_2015callsv2_18082014_en.pdf\">Template for Essential Clinical Trials Information</a><br />\r\n    &nbsp;</li>\r\n</ol>\r\n<p>&nbsp;</p>", "supportInfo": "<p>Contact the <strong>IMI&nbsp;Programme Office</strong> : E-mail:<a href=\"mailto:Infodesk@imi.europa.eu\"> Infodesk@imi.europa.eu</a>&nbsp;/ Tel: +32 2 221 81 81<br />\r\n<br />\r\nContact <strong>IMI JU&nbsp;<a href=\"mailto:sofia@imi.europa.eu\">IT Helpdesk</a></strong>&nbsp;&ndash; for IMI2 topics contact the SOFIA IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<br />\r\n<br />\r\n<a href=\"http://www.imi.europa.eu/content/states-representatives-groups\"><strong>IMI States Representative Group (SRG)</strong></a>&nbsp;&ndash; contact you SRG member for assistance.<br />\r\n<a href=\"http://www.imi.europa.eu/content/partner-search\"><br />\r\n<strong>IMI Partner Search Tool</strong></a>&nbsp;helps you find a partner organisation for your proposal<br />\r\n<strong><br />\r\n<span><a href=\"http://ec.europa.eu/research/participants/portal4/desktop/en/support/national_contact_points.html\">National Contact Points (NCP)</a>&nbsp;-&nbsp;</span></strong><span>contact your NCP for further assistance.<br />\r\n</span><br />\r\n<a href=\"http://een.ec.europa.eu/\"><strong>Enterprise Europe Network</strong></a>&nbsp;&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding<br />\r\n<strong><br />\r\n<span><a href=\"http://ec.europa.eu/research/index.cfm?lg=en&amp;pg=enquiries\">Research Enquiry Service</a></span></strong><span> &ndash; ask questions about</span>.&nbsp;any aspect of European research in general and the EU Research Framework Programmes in particular.<br />\r\n<strong><br />\r\nEthics</strong> &ndash; for compliance with ethical issues, check the information available on the<a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm\"> Participant Portal</a>&nbsp;, on the&nbsp;<a href=\"http://ec.europa.eu/research/science-society/index.cfm?fuseaction=public.topic&amp;id=1289&amp;lang=1\">Science and Society Portal</a>&nbsp;and in&nbsp;<a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\"><strong>The European Charter for Researchers and the Code of Conduct for their recruitment<br />\r\n</strong></a><a href=\"http://www.cen.eu/cen/Services/Innovation/Pages/default.aspx\"><br />\r\n<strong>CEN</strong></a> and <a href=\"http://www.cenelec.eu/aboutcenelec/whatwestandfor/fosterinnovation/randd.html\"><strong>CENELEC</strong></a>, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at <a href=\"mailto:research@cencenelec.eu\">research@cencenelec.eu</a>.<br />\r\n<a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\"><br />\r\n</a></p>", "links": [{"callIdentifier": "H2020-JTI-IMI2-2015-07-two-stage-1", "status": "Closed", "criterionType": "SubFundingScheme", "criterionTypeDescription": "subfunding schemes", "criterionCode": "IMI2-RIA", "criterionDescription": "Research and Innovation action", "url": "https://sofia.imi.europa.eu/Pages/Default.aspx", "startDate": "Dec 23, 2015 2:40:00 PM"}], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Dec 23, 2015 2:48:52 PM", "lastChangeDate": "Dec 23, 2015 2:48:52 PM", "content": "The submission session is now available for: IMI2-2015-07-01(IMI2-RIA), IMI2-2015-07-02(IMI2-RIA), IMI2-2015-07-03(IMI2-RIA), IMI2-2015-07-04(IMI2-RIA), IMI2-2015-07-05(IMI2-RIA), IMI2-2015-07-06(IMI2-RIA), IMI2-2015-07-07(IMI2-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}